





























370One-year outcomes of the U.S. and Japanese
regulatory trial of the Misago stent for treatment of
superﬁcial femoral artery disease (OSPREY study)
Takao Ohki, MD,a John F. Angle, MD,b Hiroyoshi Yokoi, MD,c Michael R. Jaff, DO,d Jeffrey Popma, MD,e
Guy Piegari, MD,f and Yuji Kanaoka, MD,a for the OSPREY investigators, Tokyo and Fukuoka, Japan;
Charlottesville, Va; Boston, Mass; and Wyomissing, Pa
Objective: The purpose of this study was to assess the safety and efﬁcacy of the Misago stent (Terumo Corp, Tokyo, Japan)
in occlusive and stenotic superﬁcial femoral artery (SFA) disease.
Methods: The safety and efﬁcacy of the Misago SFA stent were evaluated prospectively in this initial collaboration trial
between Japan and the United States. Because this trial enrolled patients mainly from Japan and the United States and
because there is a question as to whether a race difference exists in SFA stent performance, the race difference on outcome
was also analyzed. In addition, results were compared with a prior SFA stent trial.
Results: The Misago stent was implanted in 261subjects with TransAtlantic Inter-Society Consensus (TASC) type A and
type B SFA lesions (201 subjects in the United States, 50 in Japan, 9 in Taiwan, 1 in South Korea). The mean age of the
patients was 69.3 6 10.0 years, and the mean lesion length was 83.8 6 41.3 mm. The overall 12-month primary
patency rate and clinically driven target lesion revascularization were 82.9% and 13.0%, respectively. Regional differ-
ences within the Occlusive/Stenotic Peripheral Artery Revascularization Study (OSPREY) and outcomes between U.S.
and Asian patients were similar, including primary patency (82.9% vs 83.0%; P [ .889), clinically driven target lesion
revascularization (13.4% vs 11.7%; P[ .829), stent fracture rate (1.3% vs 0.0%; P[ 1.000), and stent thrombosis rate
(0.5% vs 0.0%; P [ 1.000).
Conclusions:OSPREY 12-month data showed satisfactory outcome of the Misago stent for the treatment of TASC type A
and type B SFA lesions and appears to be comparable to recent stent trials. In addition, the lack of difference in outcome
among races supports the value of international trials. (J Vasc Surg 2016;63:370-6.)1Stenting has become the most commonly performed
procedure for the treatment of superﬁcial femoral artery
(SFA) occlusive disease owing to the improved perfor-
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gates, ﬂexes, and twists, the implanted stent is subjected
to harsh mechanical stress, and therefore stent fracture re-
mains an important clinical issue.2-4 In addition, recurrent
stenosis secondary to neointimal hyperplasia, which is
partially due to the strong radial force applied to the vessel
wall by the stent, is another unsolved problem.5,6 The Mis-
ago stent (Terumo Corp, Tokyo, Japan), a nickel-titanium
bare-metal stent featuring a linkless structure that mini-
mizes the mechanical stress at the link site, may reduce
the rate of fracture. The stent showed high durability in a
bench test compared with pre-existing SFA stents.7
Furthermore, MISAGO 1 and MISAGO 2 trials, which
were performed in Europe, demonstrated low fracture
and in-stent restenosis rates and conﬁrmed the advantages
of the Misago design in a clinical setting.8-10 The Occlu-
sive/Stenotic Peripheral Artery Revascularization Study
(OSPREY) is an international trial designed to evaluate
the safety and efﬁcacy of the Misago stent for the treatment
of SFA disease in both the United States and Japan.METHODS
Study device. The Misago self-expanding stent has a
spineless linkage to avoid concentration of mechanical
stress that leads to stent fracture. The Misago self-
expanding stent system consists of a ﬂexible nitinol self-
expanding stent premounted on the distal end of a 6F
rapid exchange monorail delivery catheter system.
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single-arm, nonrandomized, prospective clinical trial. Subjects
underwent an SFA stent procedure using the Misago periph-
eral self-expanding stent. The efﬁcacy end points were evalu-
ated immediately after the procedure (adverse eventsonly) and
at 30 days, 6 months, and 12 months. Efﬁcacy was also eval-
uated at 24 and 36 months on the basis of the Rutherford
classiﬁcation, ankle-brachial index (ABI), quality of life (QoL)
questionnaires, and radiographs for evaluation of stent frac-
tures. The safety end points were evaluated immediately after
the procedure, at 30 days, and at 6, 12, 24, and 36 months.
Inclusion and exclusion criteria. The study was
approvedbyeach local InstitutionalReviewBoard.All subjects
signed a written informed consent. Major inclusion criteria
were the following: 18 years and older, Rutherford classiﬁca-
tion category 2 to 4, resting ABI of<0.9 or abnormal exercise
ABI, de novo lesion, reference vessel diameter of $4.0 mm
and #7.0 mm, and target lesion length of $40 mm and
#150 mm. Major exclusion criteria were previous bypass sur-
gery or stenting in the target SFA or distally, angiographic ev-
idence of acute thrombus, subjects with acute or chronic renal
dysfunction or estimated glomerular ﬁltration rate <30 mL/
min, severe calciﬁcation or excessive tortuosity at the target
lesion (determined by the operator), and subjects unable to
tolerate anticoagulation therapy or antiplatelet therapy.
Preprocedural evaluation. The preprocedural evalua-
tions included physical examination,medical history including
peripheral arterial disease risk factors, medications, vital signs,
complete blood count with platelet count, electrolyte panel,
Doppler ultrasound (of the target limb), QoL questions (36-
Item Short Form Health Survey, Walking Impairment Ques-
tionnaire), ABI, Rutherford classiﬁcation, and angiography.
These were assessed and performed within 30 days before the
procedure. On the basis of the preprocedural angiogram, the
investigator conﬁrmed intraoperative criteria, including lesion
morphology, assessment of inﬂow disease, and runoff vessels.
End points. The primary safety end point was deﬁned
as freedom from major adverse events (MAEs) within
30 days of the procedure that included target lesion revascu-
larization (TLR), amputation of the treated limb, and death.
The primary efﬁcacy end point was deﬁned as primary stent
patency rate at 12 months by core laboratory-read duplex
ultrasound (DUS). Patency was deﬁned by a peak systolic
velocity ratio (PSVR) <2.5 and absence of TLR through
12 months after the procedure. Secondary efﬁcacy end
points included the following: (1) technical success (deﬁned
as successful delivery of the stent with adequate lesion
coverage); (2) procedural success (attainment of <30%
residual stenosis of the target lesion and absence of
periprocedural complications deﬁned as death, stroke,
myocardial infarction, emergent surgical revascularization,
signiﬁcant distal embolization in the target limb, or throm-
bosis of the target vessel); (3) ABI; (4) clinical success (relief
or improvement of baseline symptoms as measured by the
Rutherford category for chronic limb ischemia) at 30 days
compared with baseline or sustained Rutherford category
(without increase of one ormore in theRutherford category)
at 12 months after the procedure compared with 30-dayRutherford classiﬁcation; (5) clinically driven TLR (deﬁned
as >50% stenosis with worsening symptoms or >70% ste-
nosis without symptoms); (6) patency of the target vessel
based on DUS (as determined by the PSVR <2.5 and
absence of TLR) through 12 months after the procedure;
and (7) QoL measurement (36-Item Short Form Health
Survey and the Walking Impairment Questionnaire) and
adverse events. Detailed analyses of these secondary end
points will be published in a separate manuscript.
Study organization. The OSPREY study was spon-
sored by Terumo Corporation. All the data were veriﬁed
with the source document to ensure reliability of the data.
The Clinical Events Committee (CEC) is composed of phy-
sicians who are interventional or noninterventional cardiolo-
gists not participating in this study and who are not afﬁliated
with Terumo Corporation. All data were adjudicated by the
CEC. Evaluation and analysis of all angiograms and simple
radiographs were performed by the Beth Israel Deaconess
Medical Center Angiographic Core Laboratory (Boston,
Mass), and evaluation of the DUS images was performed
by Vascular Ultrasound Core Laboratory (Boston, Mass).
These core laboratories were independent from Terumo
Corporation. Clinlogix, LLC (Ambler, Pa) and PAREXEL
(ShatinNewTerritories,HongKong)were involved asClin-
ical Research Organizations in the United States, Taiwan,
and South Korea. Clinlogix (United States), PAREXEL
(Taiwan and Korea), and Terumo (Japan) were responsible
for site management and source document veriﬁcation of
all data in each country. NAMSA (Minneapolis, Minn) was
responsible for statistical analysis of this study.
Statistical analysis. Statistical analysis included sum-
mary statistics of mean, standard deviation, standard error,
median, and range for continuous parameters and frequency
and percentage for categorical parameters. Regional
differences were compared with the c2 test or Welch t-test.
Statistical signiﬁcance was deﬁned as P < .05; there were
no adjustments for multiplicity. Kaplan-Meier estimates for
12-month patency and freedom from TLR are given at
360 days after the procedure. Statistical analyses were
performed using SAS software (version 9.3; SAS Institute,
Cary, NC). To analyze whether regional difference exists,
subanalyses were performed comparing U.S. and Asian
(Japan, Taiwan, and South Korea) subgroups.
RESULTS
Patient and lesion background. The OSPREY study
enrolled a total of 261 subjects who underwent SFA stent-
ing with the Misago stent between April 2010 and July
2012. Baseline characteristics of the patients are shown in
Table I. The mean age of the patients was 69.3 6
10.0 years, and 64.8% of the cohort was male. Approxi-
mately 91% of patients presented with claudication
(Rutherford category 2-3) and 9% with critical limb
ischemia (Rutherford category 4-6); the mean ABI was
0.7 6 0.1. Regional breakdown of the subjects is as fol-
lows: 201 from the United States; 50 from Japan; and 10
additional subjects from Taiwan and South Korea. Pre-
procedure risk factors included diabetes mellitus (47.9%),
Table I. Baseline characteristics of patients
No. of patients 261
Age, years, mean 6 SD 69.3 6 10.0






Previous vascular interventions 35.2 (92/261)
Diabetes mellitus 47.9 (125/261)
Arterial hypertension treated with medication 85.1 (222/261)
Hyperlipidemia 87.0 (227/261)
Smoking history
Yes, current 42.1 (110/261)












ABI, mean 6 SD 0.7 6 0.1
ABI, Ankle-brachial index; SD, standard deviation.
Values are reported as % (n/N) unless otherwise indicated.





Proximal SFA 12.3 (32/261)
Middle SFA 53.6 (140/261)
Distal SFA 33.3 (87/261)
Other 0.8 (2/261)
Lesion length, mm 83.8 6 41.3
Reference vessel diameter, mm 5.1 6 1.0






























NA, Not available; SFA, superﬁcial femoral artery; TASC II, TransAtlantic
Inter-Society Consensus II.
Continuous data are presented as mean 6 standard deviation, and cate-
gorical data are presented as % (n/N).
aThrombolysis in Myocardial Infarction (TIMI) 0 ﬂow refers to the absence
of any antegrade ﬂow beyond the lesion. TIMI 1 ﬂow is faint antegrade
blood ﬂow beyond the lesion, with incomplete ﬁlling of the distal vascula-
ture. TIMI 2 ﬂow is delayed or sluggish antegrade ﬂow with complete ﬁlling
of the distal vasculature. TIMI 3 is normal ﬂow.
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ing history (82.7%). Baseline characteristics of the lesions
are shown in Table II. The mean lesion length was 83.8 6
41.3 mm, mean reference vessel diameter was 5.16
1.0 mm, 31.4% had severe calciﬁed lesion, and total oc-
clusion was encountered in 24.1%.
Patient follow-up. Follow-up data were available for
240 patients (92.0%) at 12 months. The 12-month DUS
data were available for 189 patients because 23 patients had
DUS performed outside of the window period and 28
patients had no PSVR values (Fig 1).
Efﬁcacy and safety results. The primary safety and ef-
ﬁcacy end points are summarized in Table III. The
freedom from MAEs at 30 days was 99.2%, and Kaplan-
Meier survival estimate of primary patency at 12 months
was 82.9% (Fig 2). The secondary efﬁcacy and safety end
points are summarized in Table IV. Clinically driven TLR
through 12 months was 13.0%. MAEs within 30 days of
the procedure were as follows: TLR, 2 of 261 (0.8%);
amputation, 0 of 261 (0.0%); and death, 0 of 261 (0.0%).
MAEs through 12 months were noted in 42 of 261 sub-
jects (16.1%), including TLR in 34 (13.0%), amputation in
0 (0.0%), and death in 9 (3.4%). The cause of death in the
nine patients was cardiac in 3, pulmonary in 2, lung cancer
in 1, psychiatric in 1, septic shock in 1, and death of un-
known cause in 1. These deaths were reviewed by the in-
dependent CEC and were determined not to be related to
the Misago stent or the placement procedure. Three stents
were reported as fractured by the investigator. However,
one stent fracture was noted to have occurred secondary toan atherectomy procedure that was performed for the
treatment of recurrent stenosis. As a result, stent fracture
evidenced by plain radiography was present in two of 383
stents (0.5%) evaluated at 12 months. Thrombosis of the
target vessel was observed in 1 of 261 (0.4%). Any device-
related adverse event was noted in 51 of 261 subjects
(19.5%).
Regional subanalysis. Subanalysis was performed to
evaluate the presence or absence of regional differences in
terms of characteristics of the patients and lesions as well
as in outcome. When patient and lesion background was
analyzed, there were no statistically signiﬁcant differences
between the United States and Asia, except rate of
Fig 1. Flow chart of subject accountability. DUS, Duplex ultrasound; PSVR, peak systolic velocity ratio.
Table III. Primary safety and efﬁcacy outcomes
% (n/N) 95% CL
Primary safety end point
Freedom from MAEs at 30 days 99.2 (259/261) 96.2, 100.0
Primary efﬁcacy end point
Primary patency at 12 months
(ﬂat rate)
69.9 (158/226) 63.6, 75.5
TLR through 12 months 13.0 (34/261) 9.4, 17.7




CL, Conﬁdence limit; MAEs, major adverse events; TLR, target lesion
revascularization.
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.001) and preprocedural Rutherford category (United
States, 2.6 6 0.6; Asia, 2.4 6 0.6; P ¼ .033; Table V).
One-year outcome showed absence of signiﬁcant difference
between the United States and Asia for clinically driven
TLR (United States, 13.4%; Asia, 11.7%; P ¼ .829), stent
fracture rate (United States, 0.9%; Asia, 0.0%; P ¼ 1.000),
and stent thrombosis rate (United States, 0.5%; Asia, 0.0%;
P ¼ 1.000; Table VI).DISCUSSION
First-generation nitinol stent trials reported high fracture
rates (10%-20%).11,12 However, clinical trials using second-
generation stents that had improved design have shown
lower fracture rates ranging between 0.0% and 2.0%.13-15
This is a meaningful advancement because stent fracture
has been shown to be a signiﬁcant risk factor for recurrent
stenosis or reocclusion.3,4 The Misago stent embraced the
spineless linkage design because the concentration of me-
chanical stress occurred at the linkage point.7 The advantage
of this design in terms of stent durability was conﬁrmed by
preclinical bench testing. The Misago stent did not fracture
even when 650,000-cycle stress was loaded, whereas other
stents fractured after 60,000 cycles.7 In addition, the rapid
exchange system for stent delivery has been shown to reduce
radiation exposure time, facilitates more rapid device ex-
changes, and allows more accurate stent deployment.
OSPREY 1-year results showed a patency rate of 82.9%
and TLR of 13.0% despite the fact that the mean lesion
length was >80 mm. These results appear favorable
compared with recently approved bare-metal stents in the
United States. The mean lesion lengths of the OSPREY
trial, the STROLL study13 (S.M.A.R.T. Vascular Stent Sys-
tem; Cordis Corp, Fremont, Calif), and the Complete SE
Fig 2. Kaplan-Meier primary patency within 12 months. Primary patency was considered lost if the stent occluded,
target lesion revascularization (TLR) was met, or peak systolic velocity ratio (PSVR) $2.5 m/s was met. CL, Conﬁ-
dence limits.
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Vascular, Santa Rosa, Calif) were 83.8 6 41.3 mm,
77.3 6 35.3 mm, and 60.7 6 37.6 mm, respectively.
TLRs were 13.0%, 12.6%, and 8.4%; primary patency rates
were 82.9%, 81.7%, and 72.6%; and stent fracture rates
were 0.5%, 2.0%, and 0.0%, respectively. Despite the fact
that the OSPREY trial enrolled patients with longer lesions,
the 12-month outcomes are comparable to if not better
than those of other SFA stents. Zilver PTX (Cook Medical,
Bloomington, Ind) is the only approved drug-eluting stent
(DES) in United States for the SFA. The Zilver PTX ran-
domized controlled trial (RCT)15 had a mean lesion length
of 65 6 40 mm, 1-year TLR of 9.5%, primary patency rate
of 83.1%, and stent fracture rate of 0.9%. Compared with
the OSPREY trial, the lesion length of the Zilver PTX
RCT was signiﬁcantly shorter (P < .001) and 1-year out-
comes were similar, keeping in mind that the PSVR cutoff
for primary patency in the Zilver trial was <2.0. In the cor-
onary domain, late stent thrombosis (LST) after DES im-
plantation is of major concern,16 and it is well known
that the predictor of LST is the ratio of uncovered to total
stent strut area.17 Several investigators have reported that
the uncovered (unhealed) region is observed frequently
in patients with SFA treated with DES.18 The 1-year
thrombosis rate was 0.5% in the OSPREY trial and 2.6%
in the Zilver PTX RCT. It is suggested that the DES in
SFA also carries LST risk, and long-term dual antiplatelet
therapy may be necessary in these patients.
The OSPREY study was part of the Harmonization By
Doing (HBD) initiative, which represents an international
effort to develop global clinical trials and to addressregulatory barriers that may delay timely device approvals.
The OSPREY study was selected as one of the two pilot
projects intended to shorten the gap between product ap-
provals by the medical regulatory boards within the United
States (U.S. Food and Drug Administration) and Japan
(Pharmaceuticals and Medical Devices Agency). The
OSPREY study was planned to simultaneously conﬁrm
the safety and efﬁcacy in U.S. and Japanese populations.
The HBD initiative was ﬁrst launched as a pilot project
in 2003 and was publicly announced at the Japanese Circu-
lation Society Meeting in March 2004. The primary goal of
this initiative was to streamline the regulatory process for
device approval, resulting in the introduction of novel
and potentially lifesaving devices for patients in a timely
fashion. HBD represents an effort to unite regulatory
board approvals in the two countries. This combined effort
could result in more robust clinical trial data and decrease
the lag time between U.S. and Japanese regulatory
approval as well as create an improved atmosphere of aca-
demic collaboration among major academic institutions
in both countries, resulting in improved patient outcomes.
Under this HBD initiative, OSPREY enrolled in the
United States and in Asian countries, and about a quarter
of the study population was Asian. In SFA disease, it is
controversial whether cultural and racial difference be-
tween Western and Eastern populations may provide
different results. However, this study and others have not
detected regional differences.19,20 OSPREY enrolled 201
U.S. patients and 60 Asian patients in a prospective
manner. The results showed no signiﬁcant differences be-
tween the two cohorts, and thus the OSPREY study
Table V. Regional subanalysis of patient background
and lesion characteristics
United States Asia P value
Diabetes mellitus 43.8 (88/201) 61.7 (37/60) .018a
Hypertension treated
with medication
87.6 (176/201) 76.7 (46/60) .081a
Hyperlipidemia 92.0 (185/201) 70.0 (42/60) .000a
Smoking history 85.6 (172/201) 73.3 (44/60) .033a
Rutherford score 2.6 6 0.6 2.4 6 0.6 .025b
ABI 0.7 6 0.2 0.7 6 0.1 1.000b
Lesion length, mm 84.9 6 41.9 80.2 6 39.6 .428b
ABI, Ankle-brachial index.
Continuous data are presented as mean 6 standard deviation, and cate-
gorical data are presented as % (n/N).
ac2 test.
bWelch t-test.
Table VI. Regional subanalysis of 12-month results
United States Asia P value
Clinically driven TLR 13.4 (27/201) 11.7 (7/60) .829a
Stent fracture 1.7 (3/178) 0.0 (0/56) 1.000a
Stent thrombosis 0.5 (1/201) 0.0 (0/60) 1.000a
TLR, Target lesion revascularization.
Values are reported as % (n/N).
ac2 test.
Table IV. Secondary outcomes
95% CL
Technical success 100.0 (261/261) 98.3, 100.0
Successful delivery of stent at
lesion site
100.0 (261/261) 98.3, 100.0
Stent deployed in lesion with
adequate lesion coverage
100.0 (261/261) 98.3, 100.0
Procedural success 93.5 (244/261) 89.8, 96.0
ABI change from baseline to
30 days
0.3 6 0.2
ABI change from 30 days
to 12 months
0.1 6 0.2
Rutherford class sustained at
12 months from 30 days
80.2 (190/237) 74.6, 84.8
Clinically driven TLR through
12 months
13.0 (34/261) 9.4, 17.7
MAEs through 12 months 16.1 (42/261) 12.1, 21.1
TLR through 12 months 13.0 (34/261) 9.4, 17.7
Amputation through
12 months
0.0 (0/261) 0.0, 1.7
Deaths through 12 months 3.4 (9/261) 1.7, 6.5
Stent fracture through
12 months
0.5 (2/383) 0.0, 1.8
Thrombosis of target vessel 0.4 (1/261) 0.0, 2.4
Any device-related adverse event 19.5 (51/261) 15.2, 24.8
SF-36 change from baseline to
30 days
5.31 6 8.44
SF-36 change from 30 days
to 12 months
3.60 6 9.39
WIQ change from baseline to
30 days
28.58 6 32.31
WIQ change from 30 days
to 12 months
26.65 6 36.89
ABI, Ankle-brachial index; CL, conﬁdence limit; MAEs, major adverse
events; SF-36, 36-Item Short Form Health Survey; TLR, target lesion
revascularization; WIQ, Walking Impairment Questionnaire.
Continuous data are presented as mean 6 standard deviation, and cate-
gorical data are presented as % (n/N).
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the rationale of multinational study of the SFA lesion,
recognizing that the number of Asian patients was rela-
tively small and the U.S. patients were not homogeneous.
As a result of this HBD, the Misago stent gained approvalin Japan and the United States on January 14, 2015
(December 6, 2012, for bailout stenting), and May 22,
2015, respectively. When one considers the fact that
approval for the ﬁrst stent graft for abdominal aortic aneu-
rysm and for the ﬁrst stent for the SFA in Japan was 8 years
and 5 years behind U.S. approval, the effectiveness of the
HBD in minimizing the device lag problem is obvious.
Furthermore, the Misago stent is the ﬁrst “made in Japan”
Food and Drug Administration class III device to gain
approval in the United States, and this was made possible
only through this HBD effort, proving the merit of this
scheme.
CONCLUSIONS
OSPREY 12-month results showed satisfactory
outcome of the Misago stent for the treatment of SFA le-
sions up to 140 mm and appear to be comparable to
DES experience. In addition, the lack of difference in
outcome among races supports the value of international
SFA stent trials.
The authors would like to thank Kazuo Kawahara,
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